Clinical Research Directory

Inclusion Criteria: 1. Age \> 18 years 2. Clinical HHT diagnosis (8) or genetic diagnosis of HHT 3. Epistaxis at least 15 min per week. 4. COVID-19 Vaccine (2 doses) 5. Ability to give written informed consent, including compliance with the requirements of the study. Exclusion Criteria: 1. Allergy/intolerance to the study drug or related agents 2. Unstable medical illness 3. Acute infection 4. Creatinine \> ULN (upper limit of normal) 5. Liver transaminases (AST or ALT) \>= 2x ULN 6. Women participant who are pregnant or breastfeeding or plan to become pregnant during the duration of the study 7. Women of childbearing potential not on effective contraception. 8. Male participants of reproductive potential whose female partners are of childbearing potential and are not planning to use highly effective contraceptive method 9. Immunocompromised 10. History of malignancy 11. Known untreated dyslipidemia (20% above the ULN of total cholesterol and triglycerides) 12. Specific contra-indications for study drug (detailed in the product monograph)